BSLN Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold infections; ceftibuten-ledaborbactam etzadroxil, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe enterobacteriaceae infections. The company has a strategic collaboration with Prokaryotics, Inc for the development of broad-spectrum antifungal targeting drug-resistant pathogens through a differentiated mechanism of action; and Phare Bio, a biotech social venture to leverage generative artificial intelligence (AI) to transform antibiotic discovery. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.…
Industry Peers
BiotechnologyKey Statistics
About Basilea Pharmaceutica (SWX: BSLN)
›
Basilea Pharmaceutica (SWX: BSLN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 200 employees.
The shares were at 72.70 CHF on 19 November 2026, up 57.7% over 52 weeks. Its 52-week range is 45.85 CHF to 75.80 CHF: the price is 4.1% below the high and 58.6% above the low.
At a market capitalisation of 901.05M CHF, it trades at 18.1 times trailing earnings and 12.6 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 46% for BSLN.
Basilea Pharmaceutica reports return on equity of 31.5%, an operating margin of 24.2% and revenue up 14.5% year over year.
It holds more cash than debt, a net cash position of 89.61M CHF. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 99.62 CHF is 37.0% above the current price. The next earnings report is expected on 16 February 2027.